Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) --Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present the positive clinical results from both its IRD gene therapy and Phentolamine Ophthalmic Solution 0.75% (POS) programs at the following medical and industry conferences in October 2025.

“These upcoming presentations highlight the strong momentum across our pipeline, from advancing OPGx-LCA5 for patients living with an LCA5 IRD to sharing pivotal Phase 3 data from LYNX-2 in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “We look forward to engaging with the gene therapy, ophthalmology, and investor communities at these key meetings.”

Conference Participation Details:

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, please visitwww.opusgtx.com.

Source: Opus Genetics, Inc.